Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis†

Moderate‐to‐severe atopic dermatitis (AD) is a chronic disease characterized by intense, persistent and debilitating itch, resulting in sleep deprivation, signs of anxiety and depression, impaired quality of life and reduced productivity. The Peak Pruritus Numerical Rating Scale (NRS) was developed and validated as a single‐item, patient‐reported outcome (PRO) of itch severity.

[1]  M. Ardeleanu,et al.  Validation of the Peak Pruritus Numerical Rating Scale , 2019, British Journal of Dermatology.

[2]  S. Ständer,et al.  Dynamic Pruritus Score: Evaluation of the Validity and Reliability of a New Instrument to Assess the Course of Pruritus. , 2017, Acta dermato-venereologica.

[3]  S. Ständer,et al.  Itch Assessment with Visual Analogue Scale and Numerical Rating Scale: Determination of Minimal Clinically Important Difference in Chronic Itch. , 2016, Acta dermato-venereologica.

[4]  J. Silverberg,et al.  Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. , 2016, The New England journal of medicine.

[5]  A. Kimball,et al.  Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasis , 2016, The British journal of dermatology.

[6]  H. Williams,et al.  Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) , 2016, The British journal of dermatology.

[7]  T. Bieber,et al.  Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. , 2016, Journal of the American Academy of Dermatology.

[8]  E. R. Sutherland,et al.  Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial , 2016, The Lancet.

[9]  J. Cappelleri,et al.  Interpreting Change in Scores on Patient-Reported Outcome Instruments , 2016, Therapeutic innovation & regulatory science.

[10]  E. Edson-Heredia,et al.  The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis , 2015, International journal of dermatology.

[11]  J. Schmitt,et al.  Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME) , 2014, The British journal of dermatology.

[12]  E. L. Sutton.  Psychiatric disorders and sleep issues. , 2014, The Medical clinics of North America.

[13]  S. Ständer,et al.  Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials. , 2013, Acta dermato-venereologica.

[14]  S. Acaster,et al.  Methods for interpreting change over time in patient-reported outcome measures , 2013, Quality of Life Research.

[15]  Ronan A Lyons,et al.  UK health performance: findings of the Global Burden of Disease Study 2010 , 2013, BDJ.

[16]  S. Takeuchi,et al.  Visual analogue scale: evaluation of the instrument for the assessment of pruritus. , 2012, Acta dermato-venereologica.

[17]  Fleur Fritz,et al.  Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. , 2012, Acta dermato-venereologica.

[18]  Alexis Wright,et al.  Clinimetrics corner: a closer look at the minimal clinically important difference (MCID) , 2012, The Journal of manual & manipulative therapy.

[19]  S. Rapp,et al.  Differences in itch characteristics between psoriasis and atopic dermatitis patients: results of a web-based questionnaire. , 2011, Acta dermato-venereologica.

[20]  A. Armstrong,et al.  Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010 , 2011, PloS one.

[21]  L. McLeod,et al.  Interpreting patient-reported outcome results: US FDA guidance and emerging methods , 2011, Expert review of pharmacoeconomics & outcomes research.

[22]  H. Williams,et al.  Harmonising Outcome Measures for Eczema (HOME).Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany , 2010, The British journal of dermatology.

[23]  H. Murota,et al.  Showering reduces atopic dermatitis in elementary school students. , 2010, European journal of dermatology : EJD.

[24]  L. Hynan,et al.  The 5‐D itch scale: a new measure of pruritus , 2010, The British journal of dermatology.

[25]  B. L. Andersen,et al.  Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial , 2006, Allergy.

[26]  Anja Wittkowski,et al.  The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. , 2004, Journal of psychosomatic research.

[27]  T. Luger,et al.  Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme , 2004, The British journal of dermatology.

[28]  M. Graeber,et al.  The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis , 2001, Experimental dermatology.

[29]  J. Fleiss,et al.  Intraclass correlations: uses in assessing rater reliability. , 1979, Psychological bulletin.

[30]  J. Nunnally,et al.  Psychometric Theory , 2020, Encyclopedia of Behavioral Medicine.

[31]  Suephy C. Chen,et al.  Validation and Banding of the ItchyQuant: A Self-Report Itch Severity Scale. , 2017, The Journal of investigative dermatology.

[32]  C. Terwee,et al.  Quality criteria were proposed for measurement properties of health status questionnaires. , 2007, Journal of clinical epidemiology.

[33]  H. Wulf,et al.  Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients. , 2004, Acta dermato-venereologica.

[34]  M. Graeber,et al.  The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. , 2001, Experimental dermatology.

[35]  K. McGraw,et al.  Forming inferences about some intraclass correlation coefficients. , 1996 .

[36]  Jacob Cohen.  QUANTITATIVE METHODS IN PSYCHOLOGY A Power Primer , 1992 .

[37]  I I Lelis,et al.  [Atopic dermatitis]. , 1980, Vestnik dermatologii i venerologii.